Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozone versus platelet-rich plasma for lateral epicondylitis
IRCT20241211064021N9Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of platelet-rich plasma and medical ozonated water in Lateral Epicondylitis (LET) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Change in pain intensity and Quality of life. Started Nov 2025; status: completed.
02
Drugs
platelet-rich plasmamedical ozonated water
03
Conditions
Lateral Epicondylitis (LET)
Beyond the preview
Go deeper on IRCT20241211064021N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241211064021N9.